• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Omecamtiv mecarbil not associated with improved exercise capacity compared with placebo in patients with chronic heart failure with reduced ejection fraction

byZoya GomesandYuchen Dai
July 23, 2022
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, among 276 patients with chronic heart failure with reduced ejection fraction, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo when added to standard therapy.

2. These results do not support the clinical use of omecamtiv mecarbil as management for heart failure with reduced ejection fraction for improvement of exercise capacity.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The prevalence of heart failure continues to grow, affecting more than 64 million patients globally at present. Of these patients, approximately half have heart failure with a reduced left ventricular ejection fraction (HFrEF). A cardinal manifestation of HFrEF is exertional intolerance, even in stable patients. Omecamtiv mecarbil is a selective cardiac myosin activator known to improve cardiac performance and reduce the risk of cardiovascular events in patients with HFrEF. This randomized controlled trial investigated whether omecamtiv mecarbil improved peak exercise capacity in patients with chronic HFrEF. A total of 296 patients were included in this study and were randomized to receive either placebo (n=91) or omecamtiv mecarbil (n=185), given orally twice daily at a dose of either 25 mg, 37.5 mg or 50 mg based on target plasma levels, over the course of 20 weeks. The primary outcome of this study was a change in exercise capacity (peak Vo2) between baseline and week 20. Secondary outcomes included total workload, ventilatory efficiency, and daily physical activity. The change in exercise capacity (peak Vo2), for patients on omecamtiv mecarbil or placebo over 20 weeks was -0.24 vs 0.21 mL/kg/min respectively, a difference not found to be statistically significant. A major limitation to this study was the exclusion of patients with recent clinical instability, which led to the enrollment of patients with less severe HF compared with previous studies of omecamtiv mecarbil which may have limited the ability of this study to demonstrate improvements in exercise capacity.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials

RELATED REPORTS

Exercise programs associated with a lower likelihood of developing gestational diabetes in at risk pregnant women

Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

In-Depth [randomized controlled trial]: This study investigated whether omecamtiv mecarbil, a direct myosin activator, could improve peak exercise capacity in patients with chronic HFrEF. A total of 296 patients (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) were randomized 2:1 to receive either omecamtiv mecarbil (n=185) or matching placebo (n=91). The primary endpoint of this study was a change in exercise capacity (peak Vo2), and secondary endpoints included total workload, ventilatory efficiency, and daily physical activity. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak Vo2 was 14.2 mL/kg/min (IQR, 11.6-17.4) in the intervention group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. The change in exercise capacity over 20 weeks was -0.24 vs 0.21 mL/kg/min, a difference that was not statistically significant. The least square mean (LSM) treatment difference between omecamtiv mecarbil and placebo was -0.45 mL/kg/min, favoring placebo (95% CI, -1.02 to 0.13; P =.13). An analysis of secondary outcomes demonstrated LSM differences between groups in change in ventilatory efficiency (0.41 [95% CI, -0.8 to 1.6]), change in the mean daily activity (0.3 [95% CI, -0.6 to 1.1]), and change in peak workload (-5.4 W [95% CI, -10.1 to -0.7]). Adverse events experienced on omecamtiv mecarbil vs placebo respectively included, dizziness (4.9% vs 5.5%), fatigue (4.9% vs 4.4%), heart failure events (4.9% vs 4.4%), death (1.6% vs 1.1%), stroke (0.5% vs 1.1%) and myocardial infarction (0% vs 1.1%).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: exerciseheart failureHFrEF (heart failure with reduced ejection fraction)omecamtiv mecarbil
Previous Post

Use of left ventricular assist device associated with increased mortality compared to intra-aortic balloon pump in patients with cardiogenic shock from myocardial infarction

Next Post

Increasing anesthesiologist coverage responsibilities associated with increased surgical patient mortality and significant morbidity

RelatedReports

Few older adolescents meet recommended levels of physical activity
Endocrinology

Exercise programs associated with a lower likelihood of developing gestational diabetes in at risk pregnant women

August 15, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial

August 13, 2022
#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
StudyGraphics

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

August 10, 2022
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

July 28, 2022
Next Post

Increasing anesthesiologist coverage responsibilities associated with increased surgical patient mortality and significant morbidity

Pediatric palliative care outcome measures often miss quality of life

2 Minute Medicine Rewind July 25, 2022

Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment

Alcohol recovery narratives are dynamic and may be composed of multiple dimensions

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities
  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.